Novo Nordisk A/S : FDA posts briefing materials prior to

Novo Nordisk A/S : FDA posts briefing materials prior to Advisory
Committee meeting for insulin degludec and insulin degludec/insulin
aspart 
BAGSVAERD, DENMARK -- (Marketwire) -- 11/06/12 -- Novo Nordisk
announced today that the US Food and Drug Administration (FDA) has
published the briefing documents ahead of the Advisory Committee
meeting to discuss the New Drug Applications (NDA) for
insulin
degludec and insulin degludec/insulin aspart, which will take
place on 8 November 2012. 
The briefing documents from Novo Nordisk and the FDA, which will form
the basis for the Advisory Committee's discussion, provide an overview
of the non-clinical and clinical data for insulin degludec and
insulin degludec/insulin aspart for the treatment of diabetes. 
Company Announcement No 71 2012:
http://hugin.info/2013/R/1655401/534899.pdf 
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants
that: 
(i) the releases contained herein are protected by copyright and    
other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and     
originality of the information contained therein. 
Source: Novo Nordisk A/S via Thomson Reuters ONE 
[HUG#1655401] 
Further information
Media:
Mike Rulis
+45 3079 3573
mike@novonordisk.com 
Ambre Morley (US)
+1 609 216 5240
abmo@novonordisk.com 
Investors:
Kasper Roseeuw Poulsen
+45 4442 4303
krop@novonordisk.com 
Frank Daniel Mersebach
+45 4442 0604
fdni@novonordisk.com 
Lars Borup Jacobsen
+45 3075 3479
lbpj@novonordisk.com 
Jannick Lindegaard (US)
+1 609 786 4575
jlis@novonordisk.com
 
 
Press spacebar to pause and continue. Press esc to stop.